New Lipid Guideline: Early Intervention & Lp(a) Focus for CVD Prevention

A modern guideline for managing cholesterol and other blood fats, known as dyslipidemia, places increased emphasis on early lifestyle changes and the potential for initiating medical therapy even in younger adults – those as young as 30. The updated recommendations, issued jointly by the American Heart Association and the American College of Cardiology, similarly provide more detailed guidance on assessing and addressing lipoprotein(a), a genetically determined lipid that’s increasingly recognized as a risk factor for cardiovascular disease.

The guideline, published in Circulation and the Journal of the American College of Cardiology, reflects a growing understanding of the lifelong impact of cholesterol levels and the benefits of proactive management. It builds upon the 2018 guidelines, incorporating new research and assessment tools to refine risk prediction and treatment strategies. The collaborative effort involved endorsements from several organizations, including the American Association of Cardiovascular and Pulmonary Rehabilitation and the National Lipid Association.

Understanding Dyslipidemia and the New Focus on Lipoprotein(a)

Dyslipidemia encompasses a range of abnormalities in lipid levels, including low levels of high-density lipoprotein (HDL) cholesterol – often referred to as “good” cholesterol – high levels of low-density lipoprotein (LDL) cholesterol – “bad” cholesterol – elevated triglycerides, or a combination of these. “We know that each of these lipid abnormalities can contribute to the buildup of fatty deposits in the arteries and that leads to both a higher risk of heart attack and stroke,” explained Roger S. Blumenthal, MD, FACC, FAHA, director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and chair of the guideline writing committee. Healio reports.

A significant addition to the updated guideline is the greater attention given to lipoprotein(a), or Lp(a). Elevated Lp(a) levels are largely determined by genetics and can significantly increase the risk of cardiovascular events. The guideline recommends measuring Lp(a) at least once in a patient’s lifetime, and intensified management is advised for levels exceeding 125 nmol/L (or 50 mg/dL). Currently, You’ll see no specifically approved treatments to lower Lp(a), though several are under development.

Refining Risk Assessment: PREVENT Equations and Coronary Artery Calcium Scoring

Accurately assessing an individual’s risk of atherosclerotic cardiovascular disease (ASCVD) is crucial for guiding treatment decisions. The updated guideline recommends using the American Heart Association’s PREVENT equations, rather than the older Pooled Cohort Equations, for primary prevention in adults aged 30 to 75. The PREVENT equations, developed using more contemporary real-world data, incorporate factors like kidney function and social determinants of health, offering a more comprehensive risk assessment.

The guideline also suggests considering coronary artery calcium (CAC) scoring, a CT scan that measures calcium deposits in the arteries, for men aged 40 and older and women aged 45 and older. CAC scoring can help refine risk assessment, particularly in individuals with intermediate risk scores, and guide decisions about initiating lipid-lowering therapy.

Guidance for LDL-Lowering Therapy and Lifestyle Interventions

The updated guideline provides specific recommendations for LDL-lowering therapy based on an individual’s estimated ASCVD risk. This includes guidance for those with a 10-year estimated ASCVD risk of 3% to 5%, adults with diabetes, chronic kidney disease, or HIV, and individuals requiring secondary prevention after a cardiovascular event.

However, the cornerstone of dyslipidemia management remains lifestyle modification. “It’s important for patients to understand that comprehensive lifestyle modification started earlier in life and continued during adulthood and throughout the lifespan can really lower one’s risk of a heart attack and stroke,” Blumenthal emphasized. These interventions include adopting a heart-healthy diet, engaging in regular physical activity, maintaining a healthy weight, and avoiding smoking.

What This Means for Patients and Clinicians

The updated guideline signals a shift towards more proactive and personalized management of dyslipidemia. The emphasis on early intervention, particularly in younger adults, reflects the understanding that atherosclerosis – the buildup of plaque in the arteries – can begin in childhood and adolescence. The inclusion of Lp(a) as a key risk factor highlights the importance of comprehensive lipid profiling and individualized treatment strategies.

For clinicians, the guideline provides a framework for more accurately assessing risk, initiating appropriate therapies, and counseling patients on the importance of lifestyle modifications. The use of the PREVENT equations and CAC scoring can help refine risk stratification and guide treatment decisions. The guideline also underscores the need to stay informed about emerging therapies for Lp(a) and other lipid abnormalities.

Pamela B. Morris, MD, FACC, FAHA, Paul V. Palmer chair of cardiovascular disease prevention at The Medical University of South Carolina, noted that “Taking action early in life is critical because high cholesterol begins to impact your heart disease risk even in adolescence.” Healio reports.

Looking Ahead: Ongoing Research and Guideline Updates

The field of lipidology is constantly evolving, and ongoing research is expected to further refine our understanding of dyslipidemia and its management. Future studies will likely focus on developing novel therapies for Lp(a), identifying genetic factors that influence lipid metabolism, and optimizing lifestyle interventions. The American Heart Association and American College of Cardiology will continue to monitor the scientific literature and update the guideline as new evidence emerges. For the latest information, it’s important to consult official resources from these organizations and other reputable sources, such as the Centers for Disease Control and Prevention and the National Heart, Lung, and Blood Institute.